Rockefeller Capital Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $75.1M | Buy |
1,566,451
+133,378
| +9% | +$5.73M | 0.12% | 166 |
|
|
2026
Q1 | $52.7M | Buy |
1,433,073
+92,215
| +7% | +$4.37M | 0.09% | 199 |
|
|
2025
Q4 | $68.2M | Buy |
1,340,858
+584,275
| +77% | +$29.9M | 0.12% | 158 |
|
|
2025
Q3 | $42M | Buy |
756,583
+218,849
| +41% | +$12.8M | 0.08% | 220 |
|
|
2025
Q2 | $37.1M | Sell |
537,734
-120,848
| -18% | -$8.22M | 0.08% | 232 |
|
|
2025
Q1 | $45.7M | Buy |
658,582
+160,915
| +32% | +$13.3M | 0.11% | 180 |
|
|
2024
Q4 | $42.9M | Buy |
497,667
+13,081
| +3% | +$1.41M | 0.11% | 181 |
|
|
2024
Q3 | $57.7M | Sell |
484,586
-71,214
| -13% | -$9.5M | 0.16% | 142 |
|
|
2024
Q2 | $79.3M | Sell |
555,800
-19,385
| -3% | -$2.57M | 0.23% | 100 |
|
|
2024
Q1 | $73.9M | Buy |
575,185
+55,998
| +11% | +$6.67M | 0.22% | 110 |
|
|
2023
Q4 | $53.7M | Buy |
519,187
+3,457
| +0.7% | +$342K | 0.18% | 130 |
|
|
2023
Q3 | $46.9M | Buy |
515,730
+49,326
| +11% | +$4.35M | 0.18% | 132 |
|
|
2023
Q2 | $37.7M | Buy |
466,404
+16,696
| +4% | +$1.36M | 0.15% | 162 |
|
|
2023
Q1 | $35.8M | Sell |
449,708
-48,200
| -10% | -$3.42M | 0.15% | 152 |
|
|
2022
Q4 | $33.7M | Buy |
497,908
+25,984
| +6% | +$1.52M | 0.17% | 139 |
|
|
2022
Q3 | $23.5M | Sell |
471,924
-12,406
| -3% | -$665K | 0.12% | 182 |
|
|
2022
Q2 | $27M | Sell |
484,330
-28,666
| -6% | -$1.59M | 0.14% | 157 |
|
|
2022
Q1 | $28.5M | Buy |
512,996
+65,540
| +15% | +$3.36M | 0.14% | 167 |
|
|
2021
Q4 | $25.1M | Sell |
447,456
-27,218
| -6% | -$1.47M | 0.12% | 189 |
|
|
2021
Q3 | $22.8M | Buy |
474,674
+37,350
| +9% | +$1.81M | 0.12% | 192 |
|
|
2021
Q2 | $18.3M | Buy |
437,324
+124,496
| +40% | +$4.83M | 0.1% | 219 |
|
|
2021
Q1 | $10.5M | Buy |
312,828
+93,840
| +43% | +$3.34M | 0.07% | 244 |
|
|
2020
Q4 | $7.65M | Buy |
218,988
+47,480
| +28% | +$1.64M | 0.06% | 253 |
|
|
2020
Q3 | $5.95M | Buy |
171,508
+7,246
| +4% | +$242K | 0.06% | 245 |
|
|
2020
Q2 | $5.38M | Sell |
164,262
-7,686
| -4% | -$245K | 0.06% | 237 |
|
|
2020
Q1 | $5.17M | Buy |
171,948
+4,016
| +2% | +$120K | 0.07% | 216 |
|
|
2019
Q4 | $4.86M | Buy |
167,932
+36,200
| +27% | +$1M | 0.06% | 224 |
|
|
2019
Q3 | $3.4M | Buy |
131,732
+73,944
| +128% | +$1.87M | 0.05% | 229 |
|
|
2019
Q2 | $1.48M | Sell |
57,788
-6,730
| -10% | -$166K | 0.02% | 292 |
|
|
2019
Q1 | $1.69M | Buy |
64,518
+10,018
| +18% | +$246K | 0.02% | 289 |
|
|
2018
Q4 | $1.25M | Hold |
54,500
| – | – | 0.02% | 222 |
|
|
2018
Q3 | $1.28M | Sell |
54,500
-1,000
| -2% | -$24.4K | 0.02% | 192 |
|
|
2018
Q2 | $1.28M | Hold |
55,500
| – | – | 0.02% | 196 |
|
|
2018
Q1 | $1.37M | Buy |
+55,500
| New | +$1.46M | 0.02% | 194 |
|
Other funds holding NVO
F
Rockefeller Capital Management's NVO Position: Q2 2026 in Review
Rockefeller Capital Management increased its Novo Nordisk (NVO) stake by 9.3% in Q2 2026, buying an estimated $5.73M and bringing the position to 1,566,451 shares worth $75.1M. The position accounts for 0.12% of the portfolio, ranked #166.
Rockefeller Capital Management first reported a position in NVO in Q1 2018 and has held it in 34 quarters since. The position peaked at $79.3M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Rockefeller Capital Management held 1,566,451 shares of Novo Nordisk worth $75.1M as of Q2 2026.
- Rockefeller Capital Management bought 133,378 Novo Nordisk shares in Q2 2026, an estimated $5.73M.
- Novo Nordisk made up 0.12% of Rockefeller Capital Management's portfolio in Q2 2026, its #166 holding.
- Rockefeller Capital Management first reported a position in Novo Nordisk in Q1 2018 and has held it in 34 quarters since.
- Rockefeller Capital Management's Novo Nordisk position peaked at $79.3M in Q2 2024.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.